Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | NRAS Q61L |
Therapy | Chelidonine |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS Q61L | melanoma | sensitive | Chelidonine | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Chelidonine treatment inhibited activation of Nras and downstream signaling pathways, reduced proliferation and colony formation, and induced apoptosis in melanoma cells harboring NRAS Q61L in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 32156748). | 32156748 |
PubMed Id | Reference Title | Details |
---|---|---|
(32156748) | Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine. | Full reference... |